Skip to main content

Table 2 Frequency distribution of first-line therapy

From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Therapy/Year 2010 2011 2012 2013 2014 2015 All
Docetaxel 374 434 391 207 255 137 1798
  97.1% 66.0% 48.9% 22.6% 24.4% 29.0% 42.1%
  (95.0, 98.4) (62.3, 69.5) (45.4, 52.3) (20.1, 25.5) (21.9, 27.1) (25.1, 33.2) (40.6, 43.5)
Cabazitaxel 7 9 7 3 4 3 33
  1.8% 1.4% 0.9% 0.3% 0.4% 0.6% 0.8%
  (0.9, 3.7) (0.7, 2.6) (0.4, 1.8) (0.1, 1.0) (0.1, 1.0) (0.2, 1.8) (0.6, 1.1)
Sipuleucel-T 4 54 120 110 98 30 416
  1.0% 8.2% 15.0% 12.0% 9.4% 6.3% 9.7%
  (0.4, 2.6) (6.3, 10.6) (2.7, 17.6) (10.1, 14.3) (7.8, 11.3) (4.5, 8.9) (8.9, 10.7)
Radium-223 0 0 0 2 12 18 32
  0.0% 0.0% 0.0% 0.2% 1.1% 3.8% 0.7%
  (0.0, 1.0) (0.0, 0.6) (0.0, 0.5) (0.1, 0.8) (0.7, 2.0) (2.4, 5.9) (0.5, 1.1)
Abiraterone 0 161 254 515 479 162 1571
  0.0% 24.5% 31.8% 56.3% 45.8% 34.2% 36.7%
  (0.0, 1.0) (21.3, 27.9) (28.6, 35.1) (53.1, 59.5) (42.8, 48.9) (30.1, 38.6) (35.3, 38.2)
Enzalutamide 0 0 28 77 197 123 425
  0.0% 0.0% 3.5% 8.4% 18.9% 26.0% 9.9%
  (0.0, 1.0) (0.0, 0.6) (2.4, 5.0) (6.8, 10.4) (16.6, 21.3) (22.3, 30.1) (9.1, 10.9)
Total 385 658 800 914 1045 473 4275
  1. Frequency distribution of first-line therapy among 4275 patients who have a diagnosis of prostate cancer and received one of the listed focus drugs during the study period, stratified by year. Column percents and 95% confidence intervals (in parentheses) are also provided. Of note, data from 2010 to 2014 include the entire year, but data from 2015 is for only six months, January 1, 2014 through June 30, 2015
\